FDA Brief

Warning letters Drugs

FDA warning letter to

FairyGene, Inc.

High riskIssued Jul 31Posted Aug 11Center for Drug Evaluation and Research (CDER)

FDA cites FairyGene, a Bristol, PA contract manufacturer, for unsanitary facility and cleaning practices and for selling five unapproved drug balms.

What happened

FDA inspected FairyGene's drug manufacturing facility at 2 Pearl Buck Court, Suite 1, Bristol, Pennsylvania, from January 12 to 15, 2026. Investigators saw raw materials and components stored loose on floors, along walls and in hallways between packaging lines, with no labels showing contents or status, and saw drug products made in a warehouse with exposed pipes, joists and ceiling fans. FDA also reviewed product labels collected during the inspection and found five balms and creams with drug claims that do not meet over-the-counter drug rules.

What FDA found

  1. The plant had no adequate space or defined areas, so materials were stored haphazardly and could be mixed up or contaminated.

    21 CFR 211.42(b) and 211.42(c)
  2. The building itself was an unsuitable warehouse environment, with no adequate ventilation to control microbes and particles.

    21 CFR 211.42(b) and 211.42(c)
  3. Cleaning procedures were missing key details such as cleaning agents, concentrations, contact times and test limits.

    21 CFR 211.67(a) and 211.67(b)
  4. There were no cleaning or sanitization logs, cleaning steps were left blank in several batch records, and a cleaning fluid that repeatedly failed microbial tests kept being used.

    21 CFR 211.67(a) and 21 CFR 211.67(b)
  5. The quality unit did not oversee production controls, equipment qualification, stability testing or its own written duties.

    21 CFR 211.22, 211.100(a), 211.166(a), 211.22(d)
  6. Five products are unapproved new drugs because their ingredients or claimed uses do not fit the applicable over-the-counter monographs, and they are misbranded.

    FD&C Act sections 505(a), 502(ee), 301(d) and 301(a); 21 U.S.C. 355(a), 352(ee), 331(d), 331(a)

What FDA wants

FDA tells the company to correct the violations promptly and to reply in writing within 15 working days with what it has done and how it will prevent recurrence, or a reason for delay and a schedule. FDA also recommends hiring a qualified CGMP consultant to do a six-system audit before the firm seeks to resolve its compliance status.

Who should pay attention

  • brands that buy finished product from this contract manufacturer
  • companies selling wellness or beauty balms with acne, eczema or pain claims
  • firms sharing warehouses or equipment between drug and non-drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk